Cytogenetics is the branch of genetics that studies chromosomes, the tightly packed bundles of DNA inside every cell. It focuses on their number, structure, and behavior, and it’s used to diagnose conditions ranging from Down syndrome to leukemia. The field dates back to the 1840s, when thread-like structures were first observed in plant cells, but it became clinically powerful in 1956 when scientists confirmed that humans have 46 chromosomes. Since then, cytogenetic testing has become a routine part of cancer diagnosis, prenatal screening, and the workup for unexplained developmental delays.
What Cytogenetics Actually Looks At
Every human cell (with a few exceptions like red blood cells) contains 23 pairs of chromosomes, for a total of 46. These chromosomes carry all of your genetic instructions. Cytogenetics examines whether any chromosomes are missing, duplicated, broken, or rearranged. An extra copy of chromosome 21 causes Down syndrome. A missing X chromosome causes Turner syndrome. Pieces of two chromosomes can swap places, creating what’s called a translocation, which sometimes triggers cancer.
The types of changes cytogenetics can detect fall into two broad categories. The first is changes in chromosome number: having too many or too few chromosomes, a condition called aneuploidy. The second is structural changes, where parts of chromosomes are deleted, duplicated, flipped around (inversions), or swapped between chromosomes (translocations). Some of these changes are inherited, some happen randomly during early development, and some arise later in life in specific tissues, particularly in cancers.
Karyotyping: The Foundation
The most traditional cytogenetic test is a karyotype. Lab technicians collect cells, usually from a blood draw, and culture them so the cells divide. At the right moment, a chemical called colchicine freezes the cells mid-division, when chromosomes are most visible. The chromosomes are then stained with dyes that create a banding pattern, like a barcode, unique to each chromosome. A technician arranges photographs of all 46 chromosomes in order from largest to smallest and looks for anything unusual.
Karyotyping can spot large-scale problems: extra or missing chromosomes, big deletions, and translocations. Its resolution limit is roughly 5 to 10 million base pairs of DNA, meaning smaller changes slip through undetected. Standard analysis produces 450 to 550 visible bands across all chromosomes. Results typically take 7 to 14 days for bone marrow and blood samples tested for blood cancers, 14 to 21 days for constitutional (inherited) testing from blood, and up to 30 days for tissue from pregnancy losses.
For prenatal testing, fetal cells are collected through amniocentesis (usually between weeks 15 and 20 of pregnancy) or chorionic villus sampling, which takes a tiny piece of placental tissue between weeks 10 and 13. In adults, the most common sample is simply a blood draw. Bone marrow samples are used when cancer or a blood disorder is suspected.
FISH: A More Targeted Approach
Fluorescence in situ hybridization, or FISH, was developed in the early 1980s and works on a completely different principle. Instead of staining all chromosomes and scanning for visible problems, FISH uses small, custom-designed DNA probes tagged with fluorescent dyes. Each probe is built to stick to one specific region of one specific chromosome. Under a fluorescence microscope, the probe lights up wherever it finds its target sequence. If a region is missing, there’s no signal. If it’s duplicated, you see extra signals.
FISH is faster and more precise than karyotyping for known targets. Results for aneuploidy screening come back in 2 to 5 days. It’s the go-to test when doctors already suspect a specific abnormality and need a quick answer, such as confirming a chromosomal fusion in leukemia or checking for extra copies of chromosome 21 in a prenatal sample. The tradeoff is that FISH only finds what you design it to look for. It won’t catch an unexpected abnormality the way a full karyotype scan can.
Chromosomal Microarrays: Higher Resolution
Chromosomal microarray analysis, sometimes called array CGH, pushes the resolution far beyond what karyotyping can achieve. It scans the entire genome for tiny gains or losses of DNA, called copy number variants, that are too small for a microscope to detect. A study of patients with developmental delays or intellectual disability found that microarray testing identified the genetic cause in about 28% of cases, compared to 18% with conventional karyotyping. That’s roughly 2.5 times the diagnostic yield.
Microarrays have become a first-line test for children with unexplained developmental delays, intellectual disability, or birth defects. They do have blind spots: they can’t detect balanced rearrangements (where chromosome pieces swap places without any DNA being gained or lost), single-gene mutations, or very low-level mosaicism, where only a small fraction of cells carry an abnormality.
Cytogenetics in Cancer Diagnosis
Cancer cytogenetics is one of the field’s most impactful applications. Many blood cancers carry signature chromosomal changes that help doctors confirm a diagnosis, choose treatment, and predict outcomes. The most famous example is the Philadelphia chromosome, discovered in 1959 in patients with chronic myeloid leukemia (CML). It results from a swap between chromosomes 9 and 22, which fuses two genes (BCR and ABL1) into a single abnormal gene that drives uncontrolled cell growth. This discovery eventually led to a targeted drug that transformed CML from a near-fatal diagnosis into a manageable condition.
Other cancers have their own chromosomal signatures. Acute promyelocytic leukemia is defined by a translocation between chromosomes 15 and 17, which is critical to identify quickly because it changes the treatment approach entirely. Burkitt lymphoma carries a translocation involving chromosome 8 and chromosome 14 that activates a growth-promoting gene called MYC. In myelofibrosis, certain deletions or inversions signal a poor prognosis. In acute leukemias, rearrangements involving a gene called KMT2A are associated with aggressive disease.
For blood cancers, cytogenetic results directly shape treatment decisions. A patient’s karyotype at diagnosis is one of the strongest predictors of how well they’ll respond to therapy, and it’s used to classify patients into favorable, intermediate, or adverse risk groups.
Prenatal and Pediatric Uses
Prenatal cytogenetic testing is most commonly offered to people over 35 at the time of delivery, those with abnormal screening results, families with a known genetic condition, or pregnancies where an ultrasound has revealed a structural abnormality. The primary goal is detecting aneuploidy. Down syndrome (trisomy 21) is the most common chromosomal disorder, occurring in about 1 in 800 live births. Trisomy 13 and trisomy 18 also result in live births but are much rarer and far more severe. Turner syndrome, caused by a missing X chromosome, is the only survivable monosomy in humans.
FISH is often the first test sent on prenatal samples because it delivers results in days rather than weeks. A full karyotype follows to check for structural changes that FISH wouldn’t catch. For children with developmental delays or intellectual disability where initial testing is normal, chromosomal microarray has become the recommended next step because of its higher detection rate.
How Results Are Reported
Cytogenetic findings are described using a standardized international system called ISCN, which has been updated continuously for over 60 years, with the most recent revision published in September 2024. This naming system provides a universal shorthand so that a lab in one country can communicate findings precisely to a clinician in another. A normal male karyotype, for instance, is written as 46,XY. The Philadelphia chromosome translocation is written as t(9;22). This notation covers results from karyotyping, FISH, microarrays, and newer sequencing-based methods.
The field continues to expand its toolkit. While traditional microscope-based methods remain essential for detecting large rearrangements and identifying new, unexpected abnormalities, molecular techniques like microarrays and sequencing fill in the gaps at higher resolution. In practice, most clinical labs use a combination of these methods, choosing the right test based on the specific question being asked.